Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD

Abstract

TFS had significantly better quality of life and fewer hospitalisations than patients treated with TP but these improvements in health outcomes were associated with increased costs. Neither TFS nor TS are economically attractive alternatives compared with monotherapy with T.